BioSpace News Archive

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update.

iCAD, Inc. today announced that Dana Brown, President and Chief Executive Officer and Eric Lonnqvist, Chief Financial Officer, will participate at the 14th Annual Craig-Hallum Alpha Select Conference on Thursday, November 16th.

Assertio Holdings, Inc., a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that make a difference in the lives of patients, announced that Sravan Emany has been appointed to the Company’s Board of Directors.

Ocean Biomedical, Inc. Virion Therapeutics, LLC recently presented highly compelling preclinical oncology data at the annual meeting of the Society for Immunotherapy of Cancer, SITC 2023.

Viatris Inc., a global healthcare company, announced the company will participate in the Jefferies London Healthcare Conference in London, UK on Wednesday, November 15, 2023.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that the last patient has been randomized in Cohort 2 of the ADX71149 Phase 2 epilepsy clinical study.

Repairon together with the University Medical Center Göttingen and Lübeck as well as the German Center for Cardiovascular Research, announced that its Co-Founder Professor Wolfram Zimmermann held a Featured Science presentation at the American Heart Association Scientific Sessions 2023 on November 12, 2023, in Philadelphia, US.

Autifony Therapeutics Limited announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300.

Encision Inc., a medical device company owning patented Active Electrode Monitoring Technology that prevents dangerous radiant energy burns in minimally invasive surgery, announced financial results for its fiscal 2024 second quarter that ended September 30, 2023.